

Injectable Hormone Pellets

Table of Content

<u>Purpose</u>

Description & Definitions

Criteria

Coding

Document History

References

Special Notes

Keywords

Effective Date 02/2011

Next Review Date 7/15/2024

Coverage Policy Medical 157

<u>Version</u> 5

All requests for authorization for the services described by this medical policy will be reviewed per Early and Periodic Screening, Diagnostic and Treatment (EPSDT) guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*.

Purpose:

This policy addresses the medical necessity of Injectable Hormone pellets.

Description & Definitions:

Hormone pellets are injected under the skin to boost hormone levels.

Criteria:

Hormone pellets is considered not medically necessary for any indication, to include but not limited to:

• Estradiol injectable hormone pellets

Coding:

Medically necessary with criteria:

income and		
Coding	Description	
	None	

Considered Not Medically Necessary:

Coding	Description
11980	Subcutaneous hormone pellet implantation (implantation of estradiol and/or testosterone pellets beneath the skin)

U.S. Food and Drug Administration (FDA) - approved only products only.

Medical 157 Page 1 of 3

Document History:

Revised Dates:

- 2022: July
- 2021: November
- 2020: October
- 2015: March

Reviewed Dates:

- 2023: July
- 2021: October
- 2019: December
- 2018: August
- 2017: December
- 2016: February
- 2014: February
- 2013: February
- 2012: February

Effective Date:

February 2011

References:

Including but not limited to: Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2023). Retrieved June 23, 2023, from MCG 26th Edition: https://careweb.careguidelines.com/ed26/index.html

(2023). Retrieved Jun 23, 2023, from CMS: https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=estradiol+pellet&keywordType=starts&areaId=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all

(2023). Retrieved June 23, 2023, from Guideline search:

https://www.google.com/search?q=estradiol+pellets+innovative+research&rlz=1C1GCEA_enUS1019US1019&oq=estradiol+pellets+&aqs=chrome.6.69i57j0i512l4j0i22i30l3j0i15i22i30j0i22i30.100953223j0j15&sourceid=chrome&ie=UTF-8#ip=1

Estradiol Pellets. (2023). Retrieved June 23, 2023, from NATIONAL LIBRARY OF MEDICINE – Daily Med: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596a20bd-d93d-4c48-e053-2991aa0ad4ca#:~:text=The%20pellets%20provide%20constant%20estrogen,Pellet%20and%20repeat%20when%20nece ssary.

Procedure Fee Files & CPT Codes. (2023). Retrieved June 23, 2023, from Department of Medical Assistance Services: https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/ & https://www.dmas.virginia.gov/for-providers/cardinal-care-transition/

Subcutaneous Implantation Of Estradiol Pellets For Postmenopausal Disorders - ARCHIVED Jan 26, 2016. (n.d.). Retrieved June 23, 2023, from HAYES: https://evidence.hayesinc.com/report/htb.subcutaneous1958

Special Notes: *

This medical policy express Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. These policies are used when no specific guidelines for coverage are provided by the Department of Medical Assistance Services of Virginia (DMAS). Medical Policies may be superseded by state Medicaid Plan guidelines. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical 157 Page 2 of 3

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) covers services, products, or procedures for children, if those items are determined to be medically necessary to "correct or ameliorate" (make better) a defect, physical or mental illness, or condition (health problem) identified through routine medical screening or examination, regardless of whether coverage for the same service or support is an optional or limited service under the state plan. Children enrolled in the FAMIS Program are not eligible for all EPSDT treatment services. All requests for authorization for the services described by this medical policy will be reviewed per EPSDT guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to by medically necessary to correct or ameliorate the member's condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.

Keywords:

Injectable Hormone Pellets, Testosterone, SHP Medical 157, male, delayed puberty, endogenous androgen absence, hypogonadism, estradiol, Implanted Hormone Pellets, Testosterone pellet, Estradiol pellet, subcutaneous testosterone implant, Testopel® (testosterone pellets), Hormone Replacement Pellet Therapy (HRPT), bioidentical hormone replacement therapy (BHRT), subdermal implants (pellets)

Medical 157 Page 3 of 3